Press Releases Tenax Therapeutics, Inc.

Equities

TENX

US88032L6056

Market Closed - Nasdaq Other stock markets 04:30:00 2024-04-26 pm EDT			5-day change	1st Jan Change
3.48 ^USD	-3.33%		-4.13%	-84.16%

Mar. 28	Tenax Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	CI
Mar. 28	Tenax Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	CI

Press Releases

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Tenax Therapeutics to Host KOL Event: “LEVEL Setting: the Scientific Rationale for Levosimendan as a Potential First Treatment for PH-HFpEF, and the Ongoing Phase 3 LEVEL Study”	Apr. 09	AQ
Tenax Therapeutics Provides Business and Clinical Development Updates with Full Year 2023 Financial Results	Mar. 28	AQ
Tenax Therapeutics to Present at the 36th Annual Roth Conference	Mar. 12	AQ
Tenax Therapeutics Announces Oral Presentation of Levosimendan for the Treatment of PH-HFpEF at THT 2024	Feb. 29	AQ
Tenax Therapeutics Announces Global License Amendment that Significantly Expands Rights to Levosimendan	Feb. 20	AQ
Tenax Therapeutics Announces Pricing of Approximately $9 Million Public Offering	Feb. 08	AQ
Tenax Therapeutics Enrolls First Patient in Phase 3 LEVEL Study Evaluating TNX-103 (Oral Levosimendan) for the Treatment of Pulmonary Hypertension in Heart Failure with Preserved Ejection Fraction (PH-HFpEF)	Feb. 07	AQ
Tenax Therapeutics Announces USPTO Grants Notice of Allowance for U.S. Patent Application, Significantly Broadening IP Protection for Use of Levosimendan in Pulmonary Hypertension with Heart Failure with Preserved Ejection Fraction (PH-HFpEF)	Feb. 06	AQ
Tenax Therapeutics Announces Reverse Stock Split	Dec. 29	AQ
Tenax Therapeutics Announces Professor Javed Butler, M.D., M.P.H, M.B.A., joins PH-HFpEF Scientific Advisory Board	Nov. 17	AQ
Tenax Therapeutics: Q3 Earnings Snapshot	Nov. 14	AQ
Tenax Therapeutics Announces FDA Clearance of IND for TNX-103 (oral levosimendan) for the Treatment of Pulmonary Hypertension with Heart Failure with Preserved Ejection Fraction (PH-HFpEF), Initiation of Phase 3 sites expected 2023	Nov. 13	AQ
Tenax Therapeutics Issued U.S. Patent for Oral Levosimendan in Pulmonary Hypertension with Heart Failure with Preserved Ejection Fraction (PH-HFpEF)	23-07-19	AQ
Tenax Therapeutics Achieves Major Milestone as USPTO Grants Notice of Allowance for U.S. Patent Application Covering Use of Oral Levosimendan (TNX-103) in Pulmonary Hypertension with Heart Failure with Preserved Ejection Fraction (PH-HFpEF)	23-05-31	AQ
TENAX THERAPEUTICS, INC. : Other Events, Financial Statements and Exhibits (form 8-K)	23-04-13	AQ
Tenax Therapeutics Provides 2023 Business Update	23-04-12	AQ
TENAX THERAPEUTICS, INC. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS (form 10-K)	23-03-31	AQ
TENAX THERAPEUTICS, INC. : Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing (form 8-K)	23-03-30	AQ
TENAX THERAPEUTICS, INC. : Other Events, Financial Statements and Exhibits (form 8-K)	23-03-22	AQ
Tenax Announces Issuance of U.S. Patent Covering Use of IV Levosimendan in Pulmonary Hypertension with Heart Failure with Preserved Ejection Fraction (PH-HFpEF)	23-03-22	AQ

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Press Releases Tenax Therapeutics, Inc.

Equities

TENX

US88032L6056

Press Releases

Filters